Cover Image
Market Research Report

Global Anthrax Treatment Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 754236
Published Content info 103 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Anthrax Treatment Market 2019-2023
Published: November 20, 2018 Content info: 103 Pages
Description

About this market

The increase in funding for research on anthrax vaccine across the globe is likely to boost the market growth. The new funding will allow additional vaccine characterization and inspection of mucosal immune response. Technavio's analysts have predicted that the anthrax treatment market will register a CAGR of more than 8% by 2023.

Market Overview

Development of novel therapies for treatment of anthrax

There has been an increase in the development of novel therapies for anthrax due to the increasing threat of exposure to Bacillus anthracis among civilian populations and military forces.

Challenges associated with early diagnosis

There are challenges associated with early diagnosis of anthrax. Several anthrax cases have gone undetected. Such cases pose a threat to the anthrax treatment market.

For the detailed list of factors that will drive and challenge the growth of the anthrax treatment market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Bayer, and Emergent BioSolutions the competitive environment is quite intense. Factors such as the increase in development of new therapies and increase in research funding, will provide considerable growth opportunities to anthrax treatment manufactures. Bayer, Elusys Therapeutics, and Emergent BioSolutions are some of the major companies covered in this report.

'With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities. Several companies are developing vaccines and therapeutics for bioterrorism-associated anthrax including Elusys Therapeutics.'

Table of Contents
Product Code: IRTNTR30185

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

  • Pipeline analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Vaccine - Market size and forecast 2018-2023
  • Drug therapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type

PART 09: CUSTOMER LANDSCAPE

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Increase in research funding
  • Increase in development of new therapies
  • Development of vaccines against bioterrorism-associated anthrax

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer
  • Elusys Therapeutics
  • Emergent BioSolutions

PART 16: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global infectious disease treatment market
  • Exhibit 02: Segments of global infectious disease treatment market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline drugs in clinical trials
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Market condition - Five forces 2018
  • Exhibit 16: Product - Market share 2018-2023 (%)
  • Exhibit 17: Comparison by product
  • Exhibit 18: Vaccine - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 19: Vaccine - Year-over-year growth 2019-2023 (%)
  • Exhibit 20: Drug therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Drug therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Market opportunity by product
  • Exhibit 23: Customer landscape
  • Exhibit 24: Market share by geography 2018-2023 (%)
  • Exhibit 25: Geographic comparison
  • Exhibit 26: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Key leading countries
  • Exhibit 33: Market opportunity
  • Exhibit 34: Impact of drivers and challenges
  • Exhibit 35: Vendor landscape
  • Exhibit 36: Landscape disruption
  • Exhibit 37: Vendors covered
  • Exhibit 38: Vendor classification
  • Exhibit 39: Market positioning of vendors
  • Exhibit 40: Bayer - Vendor overview
  • Exhibit 41: Bayer - Business segments
  • Exhibit 42: Bayer - Organizational developments
  • Exhibit 43: Bayer - Geographic focus
  • Exhibit 44: Bayer - Segment focus
  • Exhibit 45: Bayer - Key offerings
  • Exhibit 46: Elusys Therapeutics - Vendor overview
  • Exhibit 47: Elusys Therapeutics - Organizational developments
  • Exhibit 48: Elusys Therapeutics - Key offerings
  • Exhibit 49: Emergent BioSolutions - Vendor overview
  • Exhibit 50: Emergent BioSolutions - Business segments
  • Exhibit 51: Emergent BioSolutions - Organizational developments
  • Exhibit 52: Emergent BioSolutions - Key offerings
Back to Top